Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model

Yan, Yongnian; Zou, Zhen; Sun, Yang; Xiao, Li; Xu, Kai‐Feng; Wei, Yuquan; Jin, Ningyi; Jiang, Chengyu

doi:10.1038/cr.2012.165

Cited by 325 publications

(289 citation statements)

References 13 publications

Supporting

Mentioning

283

Contrasting

Unclassified

Order By: Relevance

“…In a C57BL/6 mice model for coronavirus infection, chloroquine (50 mg/kg) protected 100% of 5-day-old suckling mice infected with human coronavirus OC43 (HCoV-OC43) when administered to pregnant mice 1 day prepartum [44]. A survival rate of 70% was observed in Balb/c mice infected with avian influenza H5N1 virus treated with chloroquine at 50 mg/kg/day [45]. These results suggest that chloroquine has the potential to inhibit ZIKV in in vivo mouse studies.…”

Section: Discussionmentioning

confidence: 99%

Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models

Delvecchio

Higa

Pezzuto

et al. 2016

Viruses

240

201

View full text Add to dashboard Cite

Zika virus (ZIKV) infection in utero might lead to microcephaly and other congenital defects. Since no specific therapy is available thus far, there is an urgent need for the discovery of agents capable of inhibiting its viral replication and deleterious effects. Chloroquine is widely used as an antimalarial drug, anti-inflammatory agent, and it also shows antiviral activity against several viruses. Here we show that chloroquine exhibits antiviral activity against ZIKV in Vero cells, human brain microvascular endothelial cells, human neural stem cells, and mouse neurospheres. We demonstrate that chloroquine reduces the number of ZIKV-infected cells in vitro, and inhibits virus production and cell death promoted by ZIKV infection without cytotoxic effects. In addition, chloroquine treatment partially reveres morphological changes induced by ZIKV infection in mouse neurospheres.

show abstract

Section: Discussionmentioning

confidence: 99%

Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models

Delvecchio

Higa

Pezzuto

et al. 2016

Viruses

240

201

View full text Add to dashboard Cite

show abstract

“…Overall chloroquine acts as a proton sponge and neutralizes the endosomal pH. The efficacy of chloroquine in influenza virus–challenged mouse studies was controversial [97, 98]. As a known antimalarial drug, chloroquine was further advanced to human clinical trials to treat influenza virus–infected human patients.…”

Section: Inhibitors Targeting Influenza a Virus Npmentioning

confidence: 99%

Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target

Sneyd

Dekant

et al. 2017

CTMC

View full text Add to dashboard Cite

Prevention and treatment of influenza virus infection is an ongoing unmet medical need. Each year, thousands of deaths and millions of hospitalizations are attributed to influenza virus infection, which poses a tremendous health and economic burden to the society. Aside from the annual influenza season, influenza viruses also lead to occasional influenza pandemics as a result of emerging or re-emerging influenza strains. Influenza viruses are RNA viruses that exist in quasispecies, meaning that they have a very diverse genetic background. Such a feature creates a grand challenge in devising therapeutic intervention strategies to inhibit influenza virus replication, as a single agent might not be able to inhibit all influenza virus strains. Both classes of currently approved anti-influenza drugs have limitations: the M2 channel blockers amantadine and rimantadine are no longer recommended for use in the U.S. due to predominant drug resistance, and resistance to the neuraminidase inhibitor oseltamivir is continuously on the rise. In pursuing the next generation of antiviral drugs with broad-spectrum activity and higher genetic barrier of drug resistance, the influenza virus nucleoprotein (NP) stands out as a high-profile drug target. This review summarizes recent developments in designing inhibitors targeting influenza NP and their mechanisms of action.

show abstract

“…The in vitro antiviral activity of chloroquine has been identified since the late 1960's (Inglot, 1969;Miller and Lenard, 1981;Shimizu et al, 1972) and the growth of many different viruses can be inhibited in cell culture by both chloroquine and hydroxychloroquine, including the SARS coronavirus (Keyaerts et al, 2004). Some evidence for activity in mice has been found for a variety of viruses, including human coronavirus OC43 (Keyaerts et al, 2009), enterovirus EV-A71 (Tan et al, 2018), Zika virus (Li et al, 2017) and influenza A H5N1 (Yan et al, 2013). However, chloroquine did not prevent influenza infection in a randomized, double-blind, placebo-controlled clinical trial (Paton et al, 2011), and had no effect on dengue-infecteds patient in a randomized controlled trial in Vietnam (Tricou et al, 2010).…”

mentioning

confidence: 99%

Of chloroquine and COVID-19

2020

View full text Add to dashboard Cite

Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model

Cited by 325 publications

References 13 publications

Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models

Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models

Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target

Of chloroquine and COVID-19

Contact Info

Product

Resources

About